Mobilising Meaningful Pharma-Patient Collaboration┃Bronwyn Lewis
Manage episode 419240601 series 3566033
On this episode, we speak with Bronwyn Lewis, Global Head of Patient Engagement at Boehringer Ingelheim.
Drawing on her 20+ years of experience across diverse roles in the pharmaceutical industry, Bronwyn offers deep insights into how the industry is perceiving and responding to the call for deeper patient engagement, the challenges and opportunities for better multi-stakeholder collaboration, and her vision for the future.
Note: In the episode, Bronwyn mentions Boehringer Ingelheim’s Research & Development (R&D) investment data for the year 2022. In 2023, Boehringer Ingelheim’s R&D investments increased by 14.2% to EUR 5.8 billion. R&D investments were substantial, at 22.5% of net sales (source: Boehringer Ingelheim strong growth pipeline acceleration 2023 | Boehringer Ingelheim (boehringer-ingelheim.com)).
Chapters
- 00:00 - Introductions
- 01:03 - Defining patient engagement from the industry perspective
- 04:06 - Bronwyn's journey into patient engagement
- 06:51 - The Patient Engagement function at Boehringer Ingelheim
- 10:39 - Composition of Patient Engagement teams in pharma
- 13:22 - Aligning the motivations of pharma and patient groups
- 16:42 - Barriers to pharma–patient collaboration
- 20:23 - Justifying return on investment (ROI)
- 26:17 - Patient engagement touchpoints and activities
- 29:16 - Matching best-fit patients to targeted activities
- 32:21 - Systemic integration of patient insights into all pharma operations
- 36:25 - Examples of patient insights influencing decisions
- 38:28 - Boehringer Ingelheim's Global Patient Partnership Summit
- 44:26 - Collaboration among industry stakeholders
- 47:56 - Visualizing the future
- 56:14 - Advice for patients and industry stakeholders
- 58:13 - Reflections with Caitlin and Clarinda
Resources and abbreviations mentioned
- Boehringer Ingelheim
- Canadian Pulmonary Fibrosis Foundation
- IPF - Idiopathic pulmonary fibrosis
- PFMD - Patient-Focused Medicines Development
- EUPATI Connect
- ROI - Return on investment
- HTA - Health Technology Assessment
- FDA - U.S. Food and Drug Administration
- EMA - European Medicines Agency
- PFMD - Pharmaceuticals and Medical Devices Agency
- GPPS - Global Patient Partnership Summit
- Patient Information Forum
- The PIF TICK
- Atomic Habits by James Clear
- EUPATI Fundamentals training
Have feedback or suggestions for us? We'd love to hear from you!
Website: notjustpatients.com
LinkedIn: Not Just Patients
Email: info@notjustpatients.com
Chapters
1. Introductions (00:00:00)
2. Defining patient engagement from the industry perspective (00:01:03)
3. Bronwyn's journey into patient engagement (00:04:06)
4. The Patient Engagement function at Boehringer Ingelheim (00:06:51)
5. Composition of Patient Engagement teams in pharma (00:10:39)
6. Aligning the motivations of pharma and patient groups (00:13:22)
7. Barriers to pharma–patient collaboration (00:16:42)
8. Justifying return on investment (ROI) (00:20:23)
9. Patient engagement touchpoints and activities (00:26:17)
10. Matching best-fit patients to targeted activities (00:29:16)
11. Systemic integration of patient insights into all pharma operations (00:32:21)
12. Examples of patient insights influencing decisions (00:36:25)
13. Boehringer Ingelheim's Global Patient Partnership Summit (00:38:28)
14. Collaboration among industry stakeholders (00:44:26)
15. Visualizing the future (00:47:56)
16. Advice for patients and industry stakeholders (00:56:14)
17. Reflections with Caitlin and Clarinda (00:58:13)
6 episodes